

An Irish Department of Genito-Urinary Medicine in the COVID-19 Era

Editor,

Genito-urinary medicine (GUM) is a high-volume, outpatient-based specialty, predominantly involving healthy young people. Our GUM clinic is the largest in south-west Ireland, with a broad catchment area. We outline the changes made to optimize safety and enhance efficiency during the COVID-19 pandemic.

Prior to national lockdown in March 2020, 50 patients were seen per clinic, with 8000 outpatient visits per year. Patients attended for testing for sexually transmitted infections (STIs), vaccination or pre-exposure prophylaxis (PrEP). Patients returned two weeks later for results, received in hard copy.

During lockdown, non-urgent care was postponed. To facilitate social distancing, maximum numbers were reduced to 27 patients per clinic, creating an immediate backlog for routine screening. To triage appointments, all patient enquiries were transferred to medical staff, requiring considerable time investment. Increased office space, computer access and technology assistance were required for medical staff. Initially, only patients

symptomatic of STI were seen in person. Screening was streamlined by removing non-essential elements, such as same-day microscopy, and introducing self-swabbing. Personal protective equipment and social distancing became mandatory. Face shields were used during pharyngeal swabbing. Laboratory results were provided electronically instead of on paper to enhance efficiency. Results were communicated by text or phone, eliminating the need for return appointments. Prescriptions were phoned or emailed to pharmacies. Topical therapies were prescribed for genital warts instead of weekly cryotherapy.

From April to August 2018, 3300 patients were seen (50% male). In the same period in 2020, 848 patients were seen, with a higher proportion of male patients (63.5%).

For female patients, the mean age was 30 years (range: 17–65). Most (306) were heterosexual, and three were bisexual. The mean number of sexual partners in the previous three months was 1.2 (range: 0–15). Most (162) were symptomatic, 129 were asymptomatic, 14 were contacts of someone with an STI, and four presented for other reasons. Bacterial vaginosis (63) and genital warts (46) were the most common diagnoses. 148 (48%) had a negative screen, of whom 89 were asymptomatic (Fig. 1).

For male patients, the mean age was 34 years (range: 18–69). Most (256) were homosexual, 243 heterosexual and 40 bisexual.




Figure 1 Diagnoses following review between April and August 2020.

Table 1 Total number of diagnoses between April and August 2018, compared with 2020. Percentage is the percentage of all patients in the time period

	April–August 2018 n (%)	April–August 2020 n (%)	Difference n (%)
Bacterial vaginosis	133 (3.9)	63 (7.4)	–70 (+3.5%)
Genital warts	121 (3.6)	135 (15.9)	+14 (+12.3%)
Chlamydia	92 (2.8)	55 (6.4)	–37 (+3.6%)
Molluscum	50 (1.5)	17 (2)	–33 (+0.5%)
Candidiasis	42 (1.3)	35 (4.1)	–7 (+2.8%)
Gonorrhoea	42 (1.2)	39 (4.5)	–3 (+3.3%)
Genital herpes	28 (0.8)	17 (2)	–11 (+1.2%)
Syphilis	30 (0.6)	10 (1.1)	–20 (+0.5%)
Negative screen	2030 (61.5%)	405 (47.8%)	–1625 (–13.7%)

The mean number of sexual partners in the previous three months was 1.7 (range: 0–15). Most (254) were asymptomatic, 227 were symptomatic, 25 were contacts of someone with an STI, and 33 presented for other reasons. Genital warts (89) and Chlamydia trachomatis (34) were the most common diagnoses. Other reasons included urethritis, epididymo-orchitis, syphilis, hepatitis, antibody testing and PrEP/PEP. 257 (47.6%) had a negative screen, of whom 149 were asymptomatic (Fig. 1).

Diagnoses in April–August 2018 and 2020 were compared (Table 1). The proportion of negative screens decreased from 61.5% (2018) to 47.8% (2020). Most conditions decreased in number during lockdown, apart from anogenital warts, which increased from 121 (3.6%) to 135 (15.9%).

Compared with 2018, there were reduced diagnoses during the COVID-19 crisis. Although the absolute number of diagnoses decreased during lockdown, the proportion of patients having symptoms or a diagnosis increased. This is expected as patients were triaged by phone, and less asymptomatic patients were seen. There was a marked reduction in bacterial infections, e.g. Chlamydia trachomatis and Neisseria gonorrhoeae, consistent with other reports.¹ This may be due to reduced numbers of sexual partners during lockdown, or due to reduced testing of asymptomatic individuals. Presentations with genital warts increased, which may be explained by delayed development following human papillomavirus infection, contracted prior to COVID-19.²

COVID-19 has profoundly reduced interpersonal exposure, with consequences for healthcare systems and sexual health. Some changes made in response to challenges have been positive and will become permanent features of our GUM service.

Conflict of interest

None declared.

Funding sources

This article has no funding sources.

D. Moriarty,¹ C. O'Connor,^{2,3,*} J. Bourke,^{2,3}
M. Murphy,^{2,3} M. Horgan,^{1,3} S. Cremin¹

¹Department of Genito-urinary Medicine, South Infirmary Victoria University Hospital, Cork, Ireland, ²Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland, ³University College Cork, Cork, Ireland

*Correspondence: C. O'Connor. E-mail: drcathaloconnor@gmail.com

References

- Crane MA, Popovic A, Stolbach AI *et al.* Reporting of sexually transmitted infections during the COVID-19 pandemic. *Sex Transm Infect* 2021; **97**: 101–102.
- Winer RL, Kiviat NB, Hughes JP, *et al.* Development and duration of human papillomavirus lesions, after initial infection. *J Infect Dis* 2005; **191**: 731–738.

DOI: 10.1111/jdv.17169

Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation

Editor,

Rapid online surveys may help illuminate patient perspectives about the SARS-COV-2 virus and the COVID-19 pandemic, allowing clinicians to address these concerns.¹ To understand patient perspectives during the early phases of the COVID-19 pandemic, the National Psoriasis Foundation (NPF) conducted a two-wave survey of a random stratified sample of individuals 18 years of age or older with psoriatic disease in the United States who recently contacted the NPF. In April and June 2020, the following questions assessed patient perspectives (IRB-approved by Genetic Alliance):

- How concerned are you (1, not at all concerned – 5, very concerned), if at all, that the current treatment(s) you take for your PsO/PsA may:
 - Increase your risk of becoming infected with COVID-19?
 - Cause you to have a worse outcome if you were to become infected with COVID-19?
- Has your healthcare provider discussed any risks associated with:
 - Your PsO/PsA and COVID-19? (Y/N).
 - The treatments for your PsO/PsA and COVID-19? (Y/N).
- How much of a threat, if any, do you feel the COVID-19 pandemic represents to your personal health? (1, not at all – 5, extremely serious threat).